Microfluidic Technology

Learn about its impact on diabetes testing

At the Consumer Electronics Show 2025, Orange Biomed showcased the OBM rapid A1c device, advancing healthcare with groundbreaking diabetes care innovation.
To improve diabetes management and patient outcomes, in 2018, NYU began offering patients A1c blood testing during emergency room visits to determine if they had diabetes.
Diabetes care for patients accounts for 1 in 4 healthcare dollars spent in the U.S. A large part of these costs is spent on diabetes-associated comorbidities.

Sign Up to Get Notified

Stay informed about our launch and get exclusive updates straight to your inbox. Fill out the form below, and we’ll make sure you’re among the first to know when OBM rapid A1c test hits the market.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.